Serum Amyloid P-Component

Amyloid P component is a small, non-fibrillar glycoprotein found in normal serum and in all amyloid deposits. It has a pentagonal (pentaxin) structure. It is an acute phase protein, modulates immunologic responses, inhibits ELASTASE, and has been suggested as an indicator of LIVER DISEASE.

Also Known As:

Networked: 282 relevant articles (2 outcomes, 25 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Pepys, Mark B: 13 articles (09/2015 - 01/2002)
2.	Hawkins, Philip N: 10 articles (09/2015 - 11/2002)
3.	Hawkins, P N: 9 articles (02/2007 - 05/2000)
4.	Hutchinson, Winston L: 8 articles (10/2012 - 01/2002)
5.	Tennent, Glenys A: 6 articles (10/2012 - 06/2005)
6.	Pepys, M B: 6 articles (05/2002 - 05/2000)
7.	Gallimore, J Ruth: 5 articles (10/2012 - 06/2005)
8.	Gillmore, J D: 5 articles (07/2001 - 05/2000)
9.	Gillmore, Julian D: 4 articles (09/2015 - 06/2004)
10.	Merchant, Soroush: 4 articles (06/2013 - 12/2007)

Related Diseases

1.	Amyloidosis 11/01/2002 - "Labelled serum amyloid P component studies thus make a unique contribution to the diagnosis and management of individual patients with systemic amyloidosis, and to systematic studies of existing and novel therapies. " 07/01/1998 - "Scintigraphic imaging and turnover studies with iodine-131 labelled serum amyloid P component in systemic amyloidosis." 04/01/1998 - "Kinetic studies with iodine-123-labeled serum amyloid P component in patients with systemic AA and AL amyloidosis and assessment of clinical value." 02/01/1993 - "This study describes the results of scintigraphy with iodine-123-labelled serum amyloid P component (SAP) as a means of establishing the distribution of organ involvement in amyloidosis. " 05/01/1991 - "Studies in vivo and in vitro of serum amyloid P component in normals and in a patient with AA amyloidosis."
2.	Amyloid Plaque 09/01/1994 - "Studies with radiolabelled serum amyloid P component provide evidence for turnover and regression of amyloid deposits in vivo." 06/01/2013 - "In a further four mice that received human serum amyloid P component (SAP) followed by anti-human SAP antibody, a treatment to eliminate visceral amyloid deposits, ECV in the liver and spleen returned to baseline after therapy (p < 0.01). " 04/01/2012 - "Serum amyloid P component (SAP) is a highly conserved plasma protein named for its universal presence in amyloid deposits. " 03/01/2010 - "Serum amyloid P component (SAP) is a universal constituent of amyloid deposits and contributes to their formation and/or persistence. " 01/01/2010 - "Serum amyloid P component which stabilizes Aβ fibrils in cortical amyloid plaques and cerebrovascular amyloid deposits significantly potentiated the barrier-weakening effect of Aβ1-42. "
3.	Alzheimer Disease (Alzheimer's Disease) 01/30/1995 - "The present study uses light and electron microscopy to compare the cerebral localization of amyloid P component in cases with (n = 19) and without (n = 15) Alzheimer's disease (AD). " 03/01/1988 - "A case of familial, atypical Alzheimer's disease: immunohistochemical study of amyloid P-component." 01/01/2012 - "Our observations support serum amyloid P component as a therapeutic target in Alzheimer's disease." 05/05/2009 - "Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component." 01/01/2008 - "Serum amyloid p component as a biomarker in mild cognitive impairment and Alzheimer's disease."
4.	Infection 10/01/2001 - "Serum amyloid P component inhibits influenza A virus infections: in vitro and in vivo studies." 02/01/2016 - "CsSAP, a teleost serum amyloid P component, interacts with bacteria, promotes phagocytosis, and enhances host resistance against bacterial and viral infection." 01/01/2002 - "Influenza virus infection is not affected by serum amyloid P component." 10/01/1997 - "Serum amyloid P component binds to influenza A virus haemagglutinin and inhibits the virus infection in vitro." 02/01/2006 - "Serum amyloid P-component (SAP), a pentraxin, is known to play an important role in innate immunity to microbial infections; however, nothing is known about it during tuberculosis (TB). "
5.	Systemic Lupus Erythematosus (Libman-Sacks Disease) 12/01/2002 - "Structural, quantitative and functional comparison of amyloid P component in sera from patients with systemic lupus erythematosus and healthy donors." 07/01/2004 - "Serum amyloid P component levels are not decreased in patients with systemic lupus erythematosus and do not rise during an acute phase reaction." 04/01/2008 - "To study serum levels of serum amyloid P component (SAP) and SAP-DNA complexes in a population-based cohort of patients with systemic lupus erythematosus (SLE). " 04/01/2008 - "Serum amyloid P component-DNA complexes are decreased in systemic lupus erythematosus. " 12/01/2005 - "To determine the presence of raised titres of anti-serum amyloid P component (SAP) antibodies in patients with systemic lupus erythematosus (SLE) and to evaluate their correlation with clinical disease by the SLEDAI and clinical manifestations. "

Related Drugs and Biologics

1.	Amyloid (Amyloid Fibrils)
2.	Proteins (Proteins, Gene)
3.	C-Reactive Protein
4.	Serum Amyloid P-Component
5.	Apolipoproteins
6.	Congo Red
7.	Antibodies
8.	Serum Amyloid A Protein (Serum Amyloid A)
9.	Blood Proteins (Serum Proteins)
10.	DNA (Deoxyribonucleic Acid)

Related Therapies and Procedures

1.	Intravenous Injections
2.	Liver Transplantation
3.	Lasers (Laser)
4.	Injections
5.	Photochemotherapy (Photodynamic Therapy)